

Current Report No 15/2022

Signing a commercial agreement for distribution of Genomtec® ID

The Management Board of Genomtec S.A. ("Issuer", "Company") announces that today, i.e., 27 June 2022, it signed an agreement (the "Agreement") with ForLab SA, a distributor based in Belgium ("Contractor") for the supply of its flagship product Genomtec® ID ("Product"). Under the Agreement, the minimum purchase values for the analyser and reaction cards will be established on a quarterly basis after the Contracting Party conducts an early market adoption assessment for the Product. The Contracting Party will have the right to exclusive distribution in Belgium, The Netherlands and Luxembourg. At the same time, pursuant to the Agreement, the Contracting Party shall not undertake cooperation within the scope of sale of other, similar devices on the territory of the above mentioned countries. The remaining provisions of the Agreement do not differ from typical conditions for this type of transactions.

The contracting Party is a trustworthy company specializing in the import and distribution of diagnostics, medical devices, and life science reagents from worldwide suppliers into Belgium, The Netherlands and Luxembourg. The company was founded in 1982 and is headquartered in Brussels. It sells to customers based in laboratories of large teaching hospitals and smaller healthcare facilities, universities, veterinary institutes, governmental laboratories, contract research organizations, pharmaceutical and biotech companies.

The Management Board of the Company considered the conclusion of the Agreement to be confidential information, because the Contracting Party declared that after an early market adoption assessment for the Product it would be ready to declare binding purchase volumes, thus there are indications that the execution of the aforementioned Agreement may have a significant impact on the Issuer's future revenue situation, as well as on the popularisation of the Company's technology and Product. Therefore, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Article 17.1 MAR.